What is AFFiRiS?
AFFiRiS is at the forefront of developing novel immunotherapies for chronic diseases, with a particular focus on neurodegenerative conditions and hypercholesterolemia. Leveraging its unique AFFITOME technology, the company is pioneering Specific Active Immunotherapies (SAIT) designed to harness the immune system to combat disease progression. This approach aims to address significant unmet medical needs by offering patients more effective treatment options with potentially less frequent dosing regimens, thereby improving overall quality of life.
How much funding has AFFiRiS raised?
AFFiRiS has raised a total of $66.1M across 4 funding rounds:
Other Financing Round
$33.9M
Private Equity
$11.3M
Other Financing Round
$10M
Other Financing Round
$10.9M
Other Financing Round (2011): $33.9M with participation from MIG Capital
Private Equity (2016): $11.3M, investors not publicly disclosed
Other Financing Round (2016): $10M supported by FCPG Affi, Santo Holding, and MIG Capital
Other Financing Round (2017): $10.9M featuring MIG Capital
Key Investors in AFFiRiS
MIG Capital
MIG Capital is a Munich-based venture capital firm specializing in innovative ideas across Europe, with a strong focus on Life Sciences and Deep Tech startups. They are known for their commitment to founders and their unique position as a retail venture capital investor in Germany.
FCPG Affi
An undisclosed investor participating in the funding round, contributing to AFFiRiS's strategic growth initiatives.
Santo Holding
An undisclosed investor participating in the funding round, contributing to AFFiRiS's strategic growth initiatives.
What's next for AFFiRiS?
The substantial enterprise-level funding and recent strategic investment position AFFiRiS for a critical phase of growth and development. This capital infusion is anticipated to fuel the advancement of its clinical trials, expand its research and development capabilities, and potentially support commercialization efforts for its innovative SAIT platforms. The company's strategic focus on chronic diseases and its proprietary technology suggest a trajectory aimed at capturing significant market share in the biopharmaceutical sector, particularly in areas with high therapeutic demand.
See full AFFiRiS company page
